|

ECC4703 Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Eccogene2

Indications

  • Liver Disease2
  • Non-alcoholic Fatty Liver Disease NAFLD1
  • Metabolic Dysfunction-Associated Steatohepatitis1
  • Dyslipidaemia1

Other1 trial

Study of ECC4703 With Sulfasalazine and Pitavastatin
Phase 1

Chandler, Arizona1 trial

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Arizona Liver Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.